Filing Details
- Accession Number:
- 0001209191-21-069644
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-14 20:27:43
- Reporting Period:
- 2021-03-30
- Accepted Time:
- 2021-12-14 20:27:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1835579 | Ikena Oncology Inc. | IKNA | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1708269 | Atlas Venture Fund Xi, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1759241 | Atlas Venture Opportunity Fund I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780065 | Atlas Venture Associates Opportunity I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780066 | Atlas Venture Associates Opportunity I, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780067 | Atlas Venture Associates Xi, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
| 1780068 | Atlas Venture Associates Xi, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-30 | 125,000 | $16.00 | 874,634 | No | 4 | P | Indirect | See footnote |
| Common Stock | Disposition | 2021-12-10 | 11,989 | $15.03 | 1,256,224 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-12-13 | 8,330 | $14.64 | 1,247,894 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-12-14 | 5,959 | $14.00 | 1,241,935 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnote |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas VentureOpportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") isthe general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
- The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.
Billionaire Hedge Funds
